SEC Form 4 · accession 0001470831-26-000802
Braveheart Bio, Inc. · BRVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erez Chimovits
Director · 10% Owner
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 4:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002131524
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $18.00 | Aug 5, 2026 | A | 30,000 | A | — | Aug 4, 2036 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
- F2Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.